BioNTech Investor Day Presentation Deck

BNT211 Clinical benefit seen in patients with testicular cancer receiving DL2 Change in target sum [%] 60 40- 20- 0- -20- -40- -60- Hi -100- Testicular -80- Ovarian Others Best response Change in target sum [%] Data cut-off: March 10, 2022. CR, complete response; DL, dose level; PR, partial response. Haanen J, et al. AACR Annual Meeting 2022; Oral presentation CT002. Durability of responses (testicular cancer) 60 40 20 0 -20- -40- -60- -80- -100- 0 10 20 Weeks 30 One patient with initial PR showed deepening of responses over time, resulting in CR Monotherapy DL1 Combination DL1 Combination DL2 Cell therapies 40 50 BIONTECH 137

View entire presentation